ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ÀûÀÀÁõº°, ¾à¹°Àü´Þ ¾ç½Äº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Small Molecule Injectable Drugs Market, By Drug Class, By Indication, By Mode of Delivery, By End User, By Geography
»óǰÄÚµå
:
1672652
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
¼¼°èÀÇ ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀº 2025³â¿¡´Â 2,347¾ï 4,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 4,104¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â¿¡ CAGR 8.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
¸®Æ÷Æ® ¹üÀ§
¸®Æ÷Æ® »ó¼¼
±âÁØ¿¬µµ
2024
2025³â ½ÃÀå ±Ô¸ð
2,347¾ï 4,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ
2020-2024³â
¿¹Ãø ±â°£
2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR :
8.30%
2032³â °¡Ä¡ ¿¹Ãø
4,104¾ï 6,000¸¸ ´Þ·¯
µµÇ¥. ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå Á¡À¯À²(%), 2025³â Áö¿ªº°
¸¸¼ºÁúȯÀÇ È®»ê°ú ¾à¹°Àü´Þ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀÌ ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀúºÐÀÚ ÀǾàǰÀº »ý¹°Á¦Á¦³ª ¹ÙÀÌ¿À½Ã¹Ð·¯¿¡ ºñÇØ ºÐÀÚ·®ÀÌ ÀÛ°í ÈÇÐÀû, ¹°¸®Àû Ư¼ºÀÌ ´Ù¸¨´Ï´Ù. Á¤¸ÆÁÖ»ç, ±ÙÀ°ÁÖ»ç, ÇÇÇÏÁÖ»ç µî ´Ù¾çÇÑ °æ·Î·Î Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±âÁ¸ ÁÖ»çÁ¦¿¡ ºñÇØ ÀúºÐÀÚ ÁÖ»çÁ¦ÀÇ ÀåÁ¡Àº ¾à¹°ÀÇ ¹æÃâ Á¶Àý, ¾ÈÁ¤¼º Çâ»ó, »ýü ÀÌ¿ë·ü Çâ»ó µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÀúºÐÀÚ ÁÖ»çÁ¦ÀÇ ´Ù¾çÇÑ Ä¡·á ¿ëµµ¿¡´Â ¾Ï, °¨¿°¼º Áúȯ, ÀÚ°¡¸é¿ªÁúȯ, ½ÉÇ÷°ü Áúȯ µîÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ ¾à¹°Àü´Þ ±â¼úÀÇ ¹ßÀü, ƯÈ÷ ³¿ë¼º ¾à¹°°ú ÀÚ°¡ Åõ¿© °¡´ÉÇÑ ÀåºñÀÇ ¹ßÀüÀº ÀÌ ½ÃÀåÀÇ ¹üÀ§¸¦ ´õ¿í È®ÀåÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ:
¼¼°èÀÇ ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀº ´Ù¾çÇÑ ¸¸¼ºÁúȯ ¹× »ý¸íÀ» À§ÇùÇÏ´Â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀÌ·¯ÇÑ Áúȯ¿¡ Ãë¾àÇÑ ³ëÀÎ Àα¸ Áõ°¡, ƯÁ¤ Ä¡·á¿¡¼ °æ±¸¿ë ¾à¹°º¸´Ù ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ÁÖ»çÁ¦ ½ÂÀο¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ Á¤Ã¥ ¹× ÀýÂ÷, ¿¬±¸°³¹ß ¹× ÀÓ»ó½ÃÇè°ú °ü·ÃµÈ ³ôÀº ºñ¿ë, ÁÖ»çÁ¦ Åõ¿©¿Í °ü·ÃµÈ ¾ÈÀü¼º ¹®Á¦ µîÀº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ÁøÃâ±â¾÷Àº ÷´ÜÀ̰í Ç¥ÀûÈµÈ ¾à¹°Àü´Þ ½Ã½ºÅÛÀ» Á¦°øÇϰí, ÁÖ»çÁ¦ ¼±ÅÃÀÌ Á¦ÇÑÀûÀÎ Ä¡·á¹ýÀ» À§ÇÑ Á¦Á¦¸¦ °³¹ßÇϸç, ȯÀÚ ¼ö°¡ ¸¹Àº ½ÅÈï ±¹°¡ °æÁ¦¿¡ ÁýÁßÇÒ ¼ö ÀÖ´Â ±âȸ°¡ ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
¼¼°èÀÇ ÀúºÐÀÚ ÁÖ»çÁ¦(ÀúºÐÀÚ ÁÖ»çÁ¦) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ¼Ò°³, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
ÁÖ¿ä ±â¾÷Àº Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck &Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Baxter, Fresenius Kabi AG, Cipla, Mylan N.V., AstraZeneca, GSK plc, Hikma Pharmaceuticals PLC, Ascletis Pharma Inc., Regeneron Pharmaceuticals Inc. µîÀÔ´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
½ÃÀå ¿ªÇÐ
¿µÇ⠺м®
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
±ÔÁ¦ ½Ã³ª¸®¿À
Á¦Ç° ¹ß¸Å/½ÂÀÎ
PEST ºÐ¼®
PORTERÀÇ »ê¾÷ ºÐ¼®
ÇÕº´°ú Àμö ½Ã³ª¸®¿À
½ÃÀå µ¿Çâ
ÁÖ¿ä ¹ßÀü
Á¦4Àå ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°, 2020-2032³â, (10¾ï ´Þ·¯)
ÀúºÐÀÚ Ç×»ýÁ¦
ÈÇпä¹ýÁ¦
°ñ°Ý±Ù À̿Ͼà
ÁøÅëÁ¦
Ç×ÀÀ°íÁ¦
Ç×°æ·Ã¾à
Ç×¹ÙÀÌ·¯½ºÁ¦
±âŸ(Ç×È÷½ºÅ¸¹ÎÁ¦¡¤Ç× ¾Ë·¹¸£±âÁ¦ µî)
Á¦5Àå ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå, ÀûÀÀÁõº°, 2020-2032³â, (10¾ï ´Þ·¯)
Á¾¾çÇÐ
ÅëÁõ °ü¸®
½ÉÇ÷°üÁúȯ
°¨¿°Áõ
ÁßÃß ½Å°æÁúȯ
±âŸ
Á¦6Àå ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå, Åõ¿© ¹æ¹ýº°, 2020-2032³â, (10¾ï ´Þ·¯)
Á¦7Àå ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2020-2032³â, (10¾ï ´Þ·¯)
º´¿ø
¿Ü·¡ Áø·á¼Ò
¿Ü·¡ ½Ã¼³
ÁÖÀÔ ¿ä¹ý ¼¾ÅÍ
±âŸ(ȨÄÉ¾î µî)
Á¦8Àå ¼¼°èÀÇ ÀúºÐÀÚ ÁÖ»çÁ¦ ½ÃÀå, Áö¿ªº°, 2020-2032³â, ±Ý¾×(10¾ï ´Þ·¯)
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
秵¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
Novartis AG
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Baxter
Fresenius Kabi AG
Cipla
Mylan N.V
AstraZeneca
GSK plc
Hikma Pharmaceuticals PLC
Ascletis Pharma Inc.
Regeneron Pharmaceuticals Inc.
Á¦10Àå ¾Ö³Î¸®½ºÆ®ÀÇ ±ÇÀå»çÇ×
Á¦11Àå Âü°í ¹®Çå°ú Á¶»ç ¹æ¹ý
Âü°í ¹®Çå
Á¶»ç ¹æ¹ý
ÃâÆÇ»ç ¼Ò°³
KSA
¿µ¹® ¸ñÂ÷
Global Small Molecule Injectable Drugs Market is estimated to be valued at USD 234.74 Bn in 2025 and is expected to reach USD 410.46 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 234.74 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
8.30%
2032 Value Projection:
USD 410.46 Bn
Figure. Small Molecule Injectable Drugs Market Share (%), By Region 2025
The growing prevalence of chronic diseases and rising demand for targeted drug delivery systems are fueling the small molecule injectable drugs market. Small molecule drugs have lower molecular weight and different chemical and physical properties compared to biologics and biosimilars. They can be administered through various routes such as intravenous, intramuscular, and subcutaneous injections. The advantages of small molecule injectable drugs over conventional injectables include controlled release of drugs, improved stability, and enhanced bioavailability. Various therapeutic applications of small molecule injectables include cancer, infectious diseases, autoimmune disorders, and cardiovascular diseases. Additionally, advancements in drug delivery technologies especially for poorly soluble drugs and self-administrable devices are further expanding the scope of this market.
Market Dynamics:
The global small molecule injectable drugs market is driven by the increasing incidence of various chronic and life-threatening conditions, growing geriatric population susceptible to such diseases, and rising preference for injectables over oral drugs in certain therapies. However, stringent regulatory policies and processes for the approval of injectable drugs, high costs associated with R&D and clinical trials, and safety issues related to drug administration through injections are some of the factors restraining the market growth. The market players have opportunities to offer advanced and targeted drug delivery systems, develop formulations for therapies having limited injectable options, and focus on emerging economies with large patient pools.
Key Features of the Study:
This report provides in-depth analysis of the global small molecule injectable drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global small molecule injectable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Baxter, Fresenius Kabi AG, Cipla, Mylan N.V, AstraZeneca, GSK plc, Hikma Pharmaceuticals PLC, Ascletis Pharma Inc., and Regeneron Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global small molecule injectable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule injectable drugs market
Market Segmentation
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
Small Molecule Antibiotics
Chemotherapy Agents
Skeletal Muscle Relaxants
Analgesics
Anticoagulants
Anticonvulsants
Antivirals
Others (Anti-histamines/Anti-allergy, etc.)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
Oncology
Pain Management
Cardiovascular Diseases
Infectious Diseases
CNS Diseases
Others
Mode of Delivery Insights (Revenue, USD Bn, 2020 - 2032)
Intravenous
Intramuscular
Subcutaneous
End User Insights (Revenue, USD Bn, 2020 - 2032)
Hospitals
Ambulatory Clinics
Outpatient Facility
Infusion Therapy Center
Others (Home Care Settings, etc.)
Regional Insights (Revenue, USD Bn, 2020 - 2032)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
Novartis AG
Pfizer, Inc.
Sun Pharmaceutical Industries Ltd.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Baxter
Fresenius Kabi AG
Cipla
Mylan N.V
AstraZeneca
GSK plc
Hikma Pharmaceuticals PLC
Ascletis Pharma Inc.
Regeneron Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Small Molecule Injectable Drugs Market, By Drug Class
Small Molecule Injectable Drugs Market, By Indication
Small Molecule Injectable Drugs Market, By Mode of Delivery
Small Molecule Injectable Drugs Market, By End User
Small Molecule Injectable Drugs Market, By Region
3. Market Dynamics, Regulations, And Trends Analysis
Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Market Trends
Key Developments
4. Small Molecule Injectable Drugs Market, By Drug Class, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Small Molecule Antibiotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Chemotherapy Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Skeletal Muscle Relaxants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Analgesics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Anticoagulants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Anticonvulsants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Antivirals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Anti-histamines/Anti-allergy, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Small Molecule Injectable Drugs Market, By Indication, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Oncology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pain Management
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Infectious Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
CNS Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Small Molecule Injectable Drugs Market, By Mode of Delivery, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Intramuscular
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Subcutaneous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Small Molecule Injectable Drugs Market, By End User, 2020-2032, (USD Bn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ambulatory Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Outpatient Facility
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Infusion Therapy Center
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Home Care Settings, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Small Molecule Injectable Drugs Market, By Region, 2020 - 2032, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
Regional Trends
North America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Mode of Delivery, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Latin America
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Mode of Delivery, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Mode of Delivery, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Mode of Delivery, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Mode of Delivery, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Mode of Delivery, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
South Africa
North Africa
Central Africa
9. Competitive Landscape
Novartis AG
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Pfizer, Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sun Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Baxter
Fresenius Kabi AG
Cipla
Mylan N.V
AstraZeneca
GSK plc
Hikma Pharmaceuticals PLC
Ascletis Pharma Inc.
Regeneron Pharmaceuticals Inc.
10. Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
11. References and Research Methodology
References
Research Methodology
About us
°ü·ÃÀÚ·á